Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Molecular evidence of bone marrow involvement in advanced case ot Tgammadelta lymphoma with secondary myelofibrosis.

Weirich G, Sandherr M, Fellbaum C, Richter T, Schmidt L, Kinjerski T, Dietzfelbinger H, Rastetter J, Höfler H.

Hum Pathol. 1998 Jul;29(7):761-5.

PMID:
9670837
2.

Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells.

Depenbrock H, Schmelcher S, Peter R, Keppler BK, Weirich G, Block T, Rastetter J, Hanauske AR.

Eur J Cancer. 1997 Dec;33(14):2404-10.

PMID:
9616290
3.

Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.

Rassmann I, Thödtmann R, Depenbrock H, Blatter J, Gatzemeier U, Rastetter J, Hanauske AR.

Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-75-S7-78.

PMID:
9194485
4.

Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study.

Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR.

Oncology. 1997 Mar-Apr;54(2):89-95.

PMID:
9075777
5.

Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.

Rassmann I, Schrödel H, Schilling T, Zucchetti M, Kaeser-Fröhlich A, Rastetter J, Hanauske AR.

Invest New Drugs. 1996;14(4):379-86.

PMID:
9157073
6.

Efficacy of 5'-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro.

Djuanda I, Depenbrock H, Peter R, Block T, Pohlmann G, Rastetter J, Hanauske AR.

Invest New Drugs. 1996;14(2):153-9.

PMID:
8913836
7.

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.

Schilling T, Keppler KB, Heim ME, Niebch G, Dietzfelbinger H, Rastetter J, Hanauske AR.

Invest New Drugs. 1996;13(4):327-32.

PMID:
8824351
8.

Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.

Hanauske AR, Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Bochtler H, Diergarten K, Rastetter J.

Semin Oncol. 1995 Dec;22(6 Suppl 14):35-9.

PMID:
8553082
9.

Beta-tubulin and P-glycoprotein: major determinants of vincristine accumulation in B-CLL cells.

Reichle A, Diddens H, Altmayr F, Rastetter J, Andreesen R.

Leuk Res. 1995 Nov;19(11):823-9.

PMID:
8551799
10.
11.

Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro.

Hanauske AR, Wüster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Fröhlich A, Rastetter J, Depenbrock H.

Eur J Cancer. 1995 Sep;31A(10):1677-81.

PMID:
7488424
12.

Interleukin 1 modulates growth of human renal carcinoma cells in vitro.

Koch I, Depenbrock H, Danhauser-Riedl S, Rastetter JW, Hanauske AR.

Br J Cancer. 1995 Apr;71(4):794-800.

13.

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

Depenbrock H, Shirvani A, Rastetter J, Hanauske AR.

Invest New Drugs. 1995;13(3):187-93.

PMID:
8729945
14.

Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.

Depenbrock H, Wenger M, Peter R, Fellbaum C, Block T, Rastetter J, Hanauske AR.

Invest New Drugs. 1995;13(2):117-23.

PMID:
8617573
15.

Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

Reichle A, Diddens H, Altmayr F, Rastetter J, Andreesen R.

Cancer Chemother Pharmacol. 1994;34(4):307-16.

PMID:
7913420
17.

Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation.

Dietzfelbinger HF, Kühn D, Zafferani M, Hanauske AR, Rastetter JW, Berdel WE.

Cancer Res. 1993 Aug 15;53(16):3747-51.

18.

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, Rastetter J, Hanauske AR.

Invest New Drugs. 1993 May-Aug;11(2-3):187-95.

PMID:
7505268
19.

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J, et al.

Eur J Cancer. 1993;29A(14):2009-14.

PMID:
7904173
20.
21.

[The mechanisms of the resistance of malignant cells to cytostatics].

Reichle A, Diddens H, Rastetter J, Berdel WE.

Dtsch Med Wochenschr. 1991 Feb 1;116(5):186-91. Review. German. No abstract available.

PMID:
1993424
22.

Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines.

Danhauser-Riedl S, Felix SB, Houlihan WJ, Zafferani M, Steinhauser G, Oberberg D, Kalvelage H, Busch R, Rastetter J, Berdel WE.

Cancer Res. 1991 Jan 1;51(1):43-8.

23.

Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.

Berdel WE, Danhauser-Riedl S, Steinhauser G, Rastetter J.

Onkologie. 1990 Dec;13(6):437-43.

PMID:
2092280
24.

Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitro.

Danhauser-Riedl S, Himmelmann A, Steinhauser G, Busch R, Vogler WR, Rastetter J, Berdel WE.

J Lipid Mediat. 1990 Sep-Oct;2(5):271-80.

PMID:
2133272
25.

Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Busch R, Modest EJ, Noseda A, Rastetter J, Vogler WR, Berdel WE.

Cancer Chemother Pharmacol. 1990;26(6):437-43.

PMID:
2225315
26.

Changes in clonal growth, immunophenotype, and morphology during a follow-up study of an acute lymphoblastic leukemia.

Reichle A, Volkmann M, Pachmann K, Diddens H, Emmerich B, Rastetter J.

Haematol Blood Transfus. 1990;33:159-65.

PMID:
2157643
27.

Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo.

Schick HD, Danhauser-Riedl S, Amtmann E, Busch R, Reichert A, Steinhauser G, Rastetter J, Sauer G, Berdel WE.

Cancer Lett. 1989 Jul 15;46(2):149-52.

PMID:
2752384
28.

Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitro.

Schick HD, Amtmann E, Berdel WE, Danhauser-Riedl S, Reichert A, Steinhauser G, Rastetter J, Sauer G.

Cancer Lett. 1989 Jul 15;46(2):143-7.

PMID:
2752383
29.

Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.

Berdel WE, Okamoto S, Danhauser-Riedl S, Hong CI, Winton EF, West CR, Rastetter J, Vogler WR.

Exp Hematol. 1989 May;17(4):364-7.

PMID:
2707318
30.

[The significance of histopathology of bone marrow for the life expectancy of patients with chronic lymphatic leukemia].

Bernhards J, Döhler U, Freund M, Rastetter J, Georgii A.

Med Klin (Munich). 1988 Oct 4;83(19):637-42. German. No abstract available.

PMID:
3185422
31.

Influence of phase I early clinical trials on the quality of life of cancer patients. A pilot study.

Berdel WE, Knopf H, Fromm M, Schick HD, Busch R, Fink U, Sellschopp A, Rastetter J.

Anticancer Res. 1988 May-Jun;8(3):313-21.

PMID:
3389737
32.

Influence of 1-beta-D-arabinofuranosylcytosine conjugates of lipids on the growth and metastasis of Lewis lung carcinoma.

Berdel WE, Danhauser S, Hong CI, Schick HD, Reichert A, Busch R, Rastetter J, Vogler WR.

Cancer Res. 1988 Feb 15;48(4):826-9.

33.

Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice.

Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmähl D, Vogler WR, Rastetter J.

Cancer Lett. 1987 Dec;38(1-2):191-7.

PMID:
2825966
34.

Antineoplastic activity of conjugates of lipids and 1-β-d-arabinofuranosylcytosine.

Berdel WE, Danhauser S, Schick HD, Hong C 2nd, West CR, Fromm M, Fink U, Reichen A, Rastetter J.

Lipids. 1987 Nov;22(11):943-6. doi: 10.1007/BF02535560.

PMID:
27519637
35.

Antineoplastic activity of conjugates of lipids and 1-beta-D-arabinofuranosylcytosine.

Berdel WE, Danhauser S, Schick HD, Hong CI, West CR, Fromm M, Fink U, Reichert A, Rastetter J.

Lipids. 1987 Nov;22(11):943-6.

PMID:
3444389
36.

Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro.

Fromm M, Berdel WE, Schick HD, Fink U, Pahlke W, Bicker U, Reichert A, Rastetter J.

Lipids. 1987 Nov;22(11):916-8.

PMID:
3444385
37.

Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro.

Danhauser S, Berdel WE, Schick HD, Fromm M, Reichert A, Fink U, Busch R, Eibl H, Rastetter J.

Lipids. 1987 Nov;22(11):911-5.

PMID:
3444384
38.

Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.

Schick HD, Berdel WE, Fromm M, Fink U, Jehn U, Ulm K, Reichert A, Eibl H, Unger C, Rastetter J.

Lipids. 1987 Nov;22(11):904-10.

PMID:
3444383
39.

Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.

Berdel WE, Korth R, Reichert A, Houlihan WJ, Bicker U, Nomura H, Vogler WR, Benveniste J, Rastetter J.

Anticancer Res. 1987 Nov-Dec;7(6):1181-7.

PMID:
3442414
40.

Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3.

Berdel WE, Fink U, Rastetter J.

Lipids. 1987 Nov;22(11):967-9.

PMID:
3328029
41.

Urinary GP41 excretion in patients with acute leukemias treated with intensive induction polychemotherapy.

Maubach PA, Emmerich B, Ogilvie A, Haas P, Hiddemann W, Rastetter J.

Haematol Blood Transfus. 1987;30:271-7. No abstract available.

PMID:
3476357
42.

Modification of tRNA and its applicability for the assessment of prognosis, state of differentiation, and clonality in human leukemias and lymphomas.

Emmerich B, Meinhardt G, Maubach PA, Zubrod E, Rastetter J, Kersten W.

Haematol Blood Transfus. 1987;30:241-50. No abstract available.

PMID:
3114059
43.

Benefit and costs of follow-up programs in nonseminomatous germ cell tumors of the stages IIb-IV: the Munich experience.

Berdel WE, Clemm C, Hartenstein R, Nisenbaum J, Fink U, Rastetter J, Wilmanns W.

Oncology. 1987;44(5):273-8.

PMID:
2823202
44.

[The Munich follow-up program in advanced non-seminoma testicular tumors. Benefits and costs].

Clemm C, Berdel WE, Hartenstein R, Nisenbaum J, Fink U, Rastetter J, Wilmanns W.

Dtsch Med Wochenschr. 1986 Aug 1;111(31-32):1181-5. German.

PMID:
3732070
45.

Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship.

Berdel WE, Von Hoff DD, Unger C, Schick HD, Fink U, Reichert A, Eibl H, Rastetter J.

Lipids. 1986 Apr;21(4):301-4.

PMID:
3713449
46.

Trisomy 7 and 8 in Ph-negative chronic eosinophilic leukemia.

Maubach PA, Bauchinger M, Emmerich B, Rastetter J.

Cancer Genet Cytogenet. 1985 Jun;17(2):159-64.

PMID:
3995497
47.
48.

[Possibilities and limitations of computerized tomography in the staging of the subdiaphragmatic spread of Hodgkin's disease].

Feuerbach S, Reiser M, Fink U, Pfafferott K, Emmerich B, Wüst I, Maubach P, Berdel WE, Rastetter J.

Dtsch Med Wochenschr. 1985 Feb 22;110(8):288-92. German.

PMID:
3971879
49.

Urinary glycoproteins in acute leukemias: a 41 000 dalton glycoprotein follows the kinetic of cytoreduction.

Maubach PA, Emmerich B, Willer A, Ogilvie A, Rastetter J.

Blut. 1984 Apr;48(4):243-6.

PMID:
6585242
50.

[Behavior of immunoglobulins following traumatologically indicated splenectomy].

Schneck HJ, von Hundelshausen B, Tempel G, Oberdorfer A, Rastetter J.

Fortschr Med. 1984 Mar 15;102(10):263-8. German.

PMID:
6714893

Supplemental Content

Loading ...
Support Center